Stephen Macfarlane

Development of a High‐Risk Medication List for Australian Residential Aged Care: A Modified Delphi Study

Amanda J. Cross, Madiha Chaudhry, Darshna Goordeen, Juanita Breen et autres

INTRODUCTION: High-risk medications are medications associated with significant patient harm or death if misused or used in error. This study aimed to develop a national consensus high-risk medication list for use in Australian residential aged care. METHODS: A 3-round modified Delphi study …

au, gb (code pays fourni par la source)

Supporting the appropriate use of psychotropic medicines in aged and disability care

Stephen Macfarlane, Julian Norman Trollor, Rebecca Koncz, Maria B. Sukkar et autres

Supporting the appropriate use of psychotropic medicines in aged and disability care SUMMARY Royal Commissions into the aged-care and disability sectors revealed significant concerns about the inappropriate use of psychotropic medicines as chemical restraint in people with cognitive disability or impairment.In response, …

au, gb (code pays fourni par la source)

Phase IIb/III ATTENTION‐AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease Patients

Marwan N. Sabbagh, Stephen Macfarlane, Audrey Gabelle, Timo Grimmer et autres

Abstract Background There are no approved oral disease‐modifying small molecule therapies for treatment of early Alzheimer’s disease (AD). Blarcamesine is an orally bioavailable small molecule that enhances autophagy through SIGMAR1 activation and restoration of cellular homeostasis in early AD. Method The ATTENTION‐AD …

us, au, fr, de (code pays fourni par la source)

Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients

Stephen Macfarlane, Timo Grimmer, Ken GW Teo, Terence John O'Brien et autres

Abstract IMPORTANCE There are no approved oral disease-modifying treatments for Alzheimer’s disease (AD) with the ability to prolong time in a stable disease state and with clinically meaningful outcomes clear to patients and caregivers. DESIGN The Phase IIb/III ANAVEX2-73-AD-004 study was a …

gb, de, au, us, Togo, pa, ie, rs, ca, jp, cn, lb, fr (code pays fourni par la source)

The Specialist Dementia Care Program in Australia: Evidence to date on a home‐like model of care for people with very severe behaviours and psychological symptoms of dementia

Mustafa Atee, Srivalli Vilapakkam Nagarajan, Rebecca Lloyd, Stephen Macfarlane et autres

OBJECTIVES: Behaviours and psychological symptoms of dementia (BPSD) have a serious impact on care and health outcomes, such as inappropriate pharmacotherapy and impaired quality of life. These symptoms are common across care settings but are more prevalent in residential aged care homes …

au (code pays fourni par la source)

Cognitive Assessment of Dementia in Incarcerated Populations: The Utility of the Addenbrooke’s Cognitive Examination 3rd Edition and the Mini-Addenbrooke’s Cognitive Examination

Ella L. Modini, Michael D. Trood, Rachael S. Fullam, Stephen Macfarlane et autres

There are many reasons why people experiencing incarceration may be predisposed to developing dementia. Dementia assessment in prisons is challenging. This study assessed the Addenbrooke's Cognitive Examination 3rd Edition (ACE-III) and the Mini Addenbrooke's Cognitive Examination (M-ACE) as potential tools for use …

au (code pays fourni par la source)

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

Stephen Macfarlane, Timo Grimmer, Ken GW Teo, Terence John O'Brien et autres

BACKGROUND: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD). OBJECTIVES: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration …

au, de, gb, in, nl, ca, fr, us (code pays fourni par la source)

Top 10 Signs and Symptoms of Psychotropic Adverse Drug Events to Monitor in Residents of Long-Term Care Facilities

Brigid E. McInerney, Amanda J. Cross, Christopher Paul Alderman, Ravi Bhat et autres

au, us, ca, fi, gb, jp, es, it, sg, cn (code pays fourni par la source)

Editorial: Behavior support for people with dementia

Stephen Macfarlane, Susan E Kurrle, Sally Grosvenor, Colm Cunningham

In the study titled "Dying with behavioral and psychological symptoms of dementia in Australian nursing homes: a retrospective case-control study," Roach et al. identified factors signalling the risk of death in people experiencing BPSD, and the need for palliative care interventions. This …

au (code pays fourni par la source)

Insights from a National Database for Programs Supporting Neuropsychiatric Symptoms of Dementia in Australia

Mustafa Atee, Thomas Morris, Daniel Whiting, Stephen Macfarlane et autres

au (code pays fourni par la source)

Estimating the Prevalence of Dementia in a sample of Australian Prisoners: The Cohort Study Design, Results and Implications for Public Health and Prison Sectors

Ella L. Modini, Margaret Nixon, Rachael S. Fullam, Stephen Macfarlane

Abstract Background The number of older prisoners within our prison system is increasing. The health challenges faced by prisoners in general contribute to prisoners being considered ‘old’ within the prison system once they reach the age of 50. The prison lifestyle, combined …

au, us (code pays fourni par la source)

Donanemab in Early Symptomatic Alzheimer Disease

John Randall Sims, Jennifer A. Zimmer, Cynthia Duggan Evans, Ming‐Chi Lu et autres

Importance: There are limited efficacious treatments for Alzheimer disease. Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. Design, Setting, and Participants: Multicenter (277 medical research centers/hospitals in 8 countries), randomized, double-blind, placebo-controlled, 18-month …

us, se (code pays fourni par la source)